![]() |
|
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Centre for Applied Pharmaceutical Research, School of Pharmacy and Pharmaceutical Sciences, University of Manchester, Manchester, United Kingdom
The substrate depletion method is a popular approach used for the measurement of in vitro intrinsic clearance (CLint). However, the incubation conditions used in these studies can vary, the consequences of which have not been systematically explored. Initial substrate depletion incubations using rat microsomes and hepatocytes were performed for eight benzodiazepines: alprazolam, clobazam, clonazepam, chlordiazepoxide, diazepam, flunitrazepam, midazolam, and triazolam. Subsequent predictions of in vivo CLint (ranging from 3 to 200 ml/min) and hepatic clearance (CLH) (ranging from 0.3 to 15 ml/min) demonstrated that the general predictive ability of this approach was similar to that of the traditional metabolite formation method. A more detailed study of the substrate depletion profiles and CLint estimates indicated that the concentration of enzyme used is of particular importance. The metabolism of triazolam, clonazepam, and diazepam was monoexponential at all cell densities using hepatocytes; however, with microsomes, biphasic depletion was apparent, particularly at higher microsomal protein concentrations (2-5 mg/ml). Enzyme activity studies indicated that enzyme loss was more pronounced in the microsomal system (ranged from 8 to 65% activity after a 1-h incubation) compared with the hepatocyte system (approximately 100% activity after a 1-h incubation). For clonazepam (a low clearance substrate), these biphasic profiles could be explained by loss of enzyme activity. To ensure accurate predictions of in vivo CLint and CLH when using the substrate depletion approach, based on the results obtained for this class of drugs, it is recommended that low enzyme concentrations and short incubation times are used whenever possible.
This article has been cited by other articles:
![]() |
G. V. Bakken, I. Rudberg, H. Christensen, E. Molden, H. Refsum, and M. Hermann Metabolism of Quetiapine by CYP3A4 and CYP3A5 in Presence or Absence of Cytochrome B5 Drug Metab. Dispos., February 1, 2009; 37(2): 254 - 258. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Sjogren, H. Lennernas, T. B. Andersson, J. Grasjo, and U. Bredberg The Multiple Depletion Curves Method Provides Accurate Estimates of Intrinsic Clearance (CLint), Maximum Velocity of the Metabolic Reaction (Vmax), and Michaelis Constant (Km): Accuracy and Robustness Evaluated through Experimental Data and Monte Carlo Simulations Drug Metab. Dispos., January 1, 2009; 37(1): 47 - 58. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. J. Kilford, R. Stringer, B. Sohal, J. B. Houston, and A. Galetin Prediction of Drug Clearance by Glucuronidation from in Vitro Data: Use of Combined Cytochrome P450 and UDP-Glucuronosyltransferase Cofactors in Alamethicin-Activated Human Liver Microsomes Drug Metab. Dispos., January 1, 2009; 37(1): 82 - 89. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Gertz, P. J. Kilford, J. B. Houston, and A. Galetin Drug Lipophilicity and Microsomal Protein Concentration as Determinants in the Prediction of the Fraction Unbound in Microsomal Incubations Drug Metab. Dispos., March 1, 2008; 36(3): 535 - 542. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. K. Kuester and I. G. Sipes Prediction of Metabolic Clearance of Bisphenol A (4,4 '-Dihydroxy-2,2-diphenylpropane) using Cryopreserved Human Hepatocytes Drug Metab. Dispos., October 1, 2007; 35(10): 1910 - 1915. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Zhang, D. Zhang, W. Li, M. Yao, C. D'Arienzo, Y.-X. Li, W. R. Ewing, Z. Gu, Y. Zhu, N. Murugesan, et al. Reduction of Site-Specific CYP3A-Mediated Metabolism for Dual Angiotensin and Endothelin Receptor Antagonists in Various in Vitro Systems and in Cynomolgus Monkeys Drug Metab. Dispos., May 1, 2007; 35(5): 795 - 805. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Nath and W. M. Atkins A Theoretical Validation of the Substrate Depletion Approach to Determining Kinetic Parameters Drug Metab. Dispos., September 1, 2006; 34(9): 1433 - 1435. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Lu, P. Li, R. Gallegos, V. Uttamsingh, C. Q. Xia, G. T. Miwa, S. K. Balani, and L.-S. Gan Comparison of Intrinsic Clearance in Liver Microsomes and Hepatocytes from Rats and Humans: Evaluation of Free Fraction and Uptake in Hepatocytes Drug Metab. Dispos., September 1, 2006; 34(9): 1600 - 1605. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. Hallifax, H. C. Rawden, N. Hakooz, and J. B. Houston PREDICTION OF METABOLIC CLEARANCE USING CRYOPRESERVED HUMAN HEPATOCYTES: KINETIC CHARACTERISTICS FOR FIVE BENZODIAZEPINES Drug Metab. Dispos., December 1, 2005; 33(12): 1852 - 1858. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Giuliano, M. Jairaj, C. M. Zafiu, and R. Laufer DIRECT DETERMINATION OF UNBOUND INTRINSIC DRUG CLEARANCE IN THE MICROSOMAL STABILITY ASSAY Drug Metab. Dispos., September 1, 2005; 33(9): 1319 - 1324. [Abstract] [Full Text] [PDF] |
||||